FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology. Disclosed is a method of preparing a purified conjugate in a solution, involving bringing into contact a maytansinoid molecule containing a thiol group, with a heterobifunctional linker reagent for covalent bonding of linker to maytansinoid molecule, then conjugation of antibody with maytansinoid molecule associated with linkers, by reacting obtained crude mixture with antibody in a solution having pH from approximately 4 to approximately 9, and applying to produced mixture tangential flow filtration, dialysis, gel filtration, adsorption chromatography, selective deposition or combination thereof to produce purified conjugate.
EFFECT: disclosed method requires no purification of intermediate compounds, provides high output of conjugates of high purity and homogeneity without inter-chain crosslinking and inactivated residues of linker and can find further application in production of medicinal preparations based on corresponding conjugates.
9 cl, 25 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATION METHODS | 2010 |
|
RU2765240C2 |
| CD37 BINDING MOLECULES AND IMMUNOCONJUGATES | 2011 |
|
RU2610662C9 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| ANTI-CD20 ANTIBODIES AND THEREOF APPLICATION | 2011 |
|
RU2573994C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| CD37-BINDING MOLECULES AND THEIR IMMUNOCONJUGATES | 2011 |
|
RU2742743C2 |
| CD138-TARGETED CELL AGENTS AND USING THEM | 2008 |
|
RU2537265C2 |
| METHOD FOR IMPROVING TARGETED ACTION OF CD138 EXPRESSING TUMOUR CELLS AND AGENTS TO THIS EFFECT | 2008 |
|
RU2486203C2 |
| MATERIALS AND METHODS ASSOCIATED WITH LINKERS FOR USE IN DRUG AND PROTEIN CONJUGATES | 2015 |
|
RU2737553C2 |
| ANTI-CD138 IMMUNOCONJUGATES AND USING THEM | 2008 |
|
RU2547939C2 |
